Printer Friendly


 TROY, Mich., Dec. 7 /PRNewswire/ -- R.P. Scherer Corporation (NYSE: SHR) announced today that its U.K. operation, Scherer DDS Limited, has entered into a $500,000 Research Agreement under the Link Initiative in Selective Drug Delivery and Targeting with three U.K. university centers at Strathclyde and Nottingham. The Research will determine the optimum conditions for delivering drugs to the colon, the area of the gastro-intestinal tract considered significant for the absorption of peptides. Colon-targeted drug delivery is also important for the treatment of inflammatory bowel diseases, such as ulcerative colitis and irritable bowel syndrome. The Research is expected to yield valuable information on the effects of dosing relative to food intake, as well as the influences of rest, posture and diurnal rhythms on colonic residence time.
 The investigations will utilize Scherer's Pulsincap(R) dosage form, which has been shown to provide an excellent means of targeting delivery of drug substances to the colon. The Pulsincap(R) dosage consists essentially of an impermeable capsule body, containing the drug, sealed with a hydrogel plug. In aqueous media the plug hydrates, swells and, after a time period defined by the plug dimensions, is ejected from the device, thereby releasing the capsule contents. For delivery to the colon, an enteric or pH-sensitive coat is applied to the Pulsincap(R) device.
 Under the Research Agreement, a three year program of work will be jointly funded under Link by U.K. Government sponsors and Scherer DDS Limited. Any intellectual property arising from the research will be offered first to Scherer DDS Limited for commercial development.
 R.P. Scherer Corporation, an international developer and manufacturer of drug delivery systems, is the world's largest producer of soft gelatin capsules ("softgels"). The Company is currently developing and commercializing advanced drug delivery systems, including SCHERERSOL(TM), ZYDIS(R) and PULSINCAP(R) technologies. The Company's proprietary drug delivery systems improve the efficacy of drugs by regulating the dosage, rate of absorption and place of release. The Company operates a global network of 18 facilities in 11 countries.
 -0- 12/7/93
 /CONTACT: Nicole Williams, Executive VP & CFO of R.P. Scherer, 313-649-0900/

CO: R.P. Scherer Corporation ST: Michigan IN: MTC SU:

KE -- DE005 -- 1172 12/07/93 09:39 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 7, 1993

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters